Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Lung Neoplasms 9Prostatic Neoplasms 7Breast Neoplasms 5Head and Neck Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Pancreatic Neoplasms 2Lymphoma 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Vasculitis 1Uterine Cervical Neoplasms 1Solid Tumor, Adult 1Smoking Cessation 1Sinusitis 1Rectal Neoplasms 1Postoperative Complications 1Osteomyelitis 1Nose Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Multiple Pulmonary Nodules 1Metastatic Solid Tumors 1Melanoma 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, Non-Hodgkin 1

Interventions

sacituzumab govitecan 1bintrafusp alfa protein, human 1avelumab 1Tomography, X-Ray Computed 1Nivolumab 1Ipilimumab 1Gemcitabine 1Electrocardiography 1Echocardiography 1DOXO-EMCH 1(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Metastatic Solid Tumors × Tomography, X-Ray Computed × Clear all
NCT03388632 2025-12-18

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
31 enrolled 20 charts
Other solid neoplasm

Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡